Dayro Enrique Rodelo barrios

Prof. Dayro Enrique Rodelo barrios

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 March 2023 in Biomolecules
Verified
Journal Article
Open access
PDF file
Jorge Rico FontalvoJorge Rico Fontalvo
Jorge Rico Fontalvo
GAGustavo Aroca
Gustavo Aroca
RDRodrigo Daza-Arnedo
Rodrigo Daza-Arnedo
JCJose Cabrales
Jose Cabrales
TYTomas Rodriguez Yanez
Tomas Rodriguez Yanez
EOElber Luis Osorio-Rodriguez
Elber Luis Osorio-Rodriguez
Diabetic kidney disease (DKD) is a highly prevalent condition worldwide. It represents one of the most common complications arising from diabetes mellitus (DM) and is the leading cause of end-stage kidney disease (ESKD). Its development involves three fundamental components: the hemodynamic, metabolic, and inflammatory axes. Clinically, persistent albuminuria in association with a progressive decline in glomerular filtration rate (GFR) defines this disease. However, as these alterations are not specific to DKD, there is a need to discuss novel biomarkers arising from its pathogenesis which may aid in the diagnosis, follow-up, therapeutic response, and prognosis of the disease.

3 April 2024 in Kidney and Dialysis
Verified
Journal Article
Open access
PDF file
EOElber Luis Osorio-Rodriguez
Elber Luis Osorio-Rodriguez
DBDayro Enrique Rodelo barrios
Dayro Enrique Rodelo barrios
CRCarlos Rebolledo-Maldonado
Carlos Rebolledo-Maldonado
APAlberto Polo-Barranco
Alberto Polo-Barranco
JPJhonny Jesus Patiño
Jhonny Jesus Patiño
ABAlfonso Bettin-Martínez
Alfonso Bettin-Martínez
Leptospirosis is a re-emerging zoonotic disease that has had an unprecedented impact on most health systems in the world. The spectrum of symptoms is variable and usually ranges from asymptomatic cases to severe manifestations involving multiple organ dysfunction accompanied by jaundice, hemorrhage, meningitis, and acute kidney injury that requires the need for intensive care assistance. Although early antibiotic treatment is usually effective, in severe cases, it may require renal replacement therapy, invasive mechanical ventilation, vasoactive support, and invasive hemodynamic monitoring, increasing the risk of death. In Latin America, the real burden of acute kidney injury in this condition is unknown and may be underestimated due to the rapid progression of the disease, similar to other vector zoonoses, and the low coverage of diagnostic tests in primary care, especially in rural regions. Therefore, below, we review the clinical aspects and describe the scientific, clinical, and therapeutic evidence of acute kidney injury attributed to Leptospira spp. and its relevance in patients with severe leptospirosis in Latin America.

Verified
Journal Article
Open access
PDF file
APAlberto Polo-Barranco
Alberto Polo-Barranco
CRCarlos Rebolledo-Maldonado
Carlos Rebolledo-Maldonado
VEValeria Esquiaqui-Rangel
Valeria Esquiaqui-Rangel
ANAndrea Nuñez-Mejia
Andrea Nuñez-Mejia
JRJeisón Rambal-Torres
Jeisón Rambal-Torres
EOElber Luis Osorio-Rodriguez
Elber Luis Osorio-Rodriguez
Even when people with diabetes mellitus (DM) meet their cholesterol goals, they still face a higher risk of heart and blood vessel problems. One major reason is a particle called lipoprotein(a), or Lp(a), which is similar to LDL cholesterol. Raised levels of Lp(a) are inherited rather than caused by lifestyle. Lp(a) can build up in the body and make it easier for blood clots to form because it closely resembles a protein called plasminogen, reducing its ability to form plasmin that dissolves blood clots. At the same time, chemical changes like oxidation and glycation can make blood vessels more inflamed, adding to the risk. Elevated concentrations of Lp(a) (>30 mg/dL; 75 nmol/L), and particularly >50 mg/dL (125 nmol/L), are independently associated with coronary artery disease, ischemic stroke, diabetic nephropathy, retinopathy, and neuropathy. Conventional lipid-lowering therapies exert neutral or modest effects on Lp(a), in contrast to RNA-based targeted agents (antisense oligonucleotides and siRNA [Small Interfering RNA]), which achieve reductions of 70–95% and show consistent results in Phase 2 clinical trials. In this review, we bring together findings from laboratory research and clinical studies, and highlight why it is important to measure Lp(a) levels—at least once in a person’s life, and especially in those with diabetes—to help doctors better assess risk and plan more effective treatments. In diabetic populations, the adaptation of Lp(a)-targeted therapies could redefine the management of residual risk and improve both cardiovascular and microvascular outcomes.

Verified
Journal Article
Open access
PDF file
EOElber Luis Osorio-Rodriguez
Elber Luis Osorio-Rodriguez
Jose Alfredo Correa GuerreroJose Alfredo Correa Guerrero
Jose Alfredo Correa Guerrero
DBDayro Enrique Rodelo barrios
Dayro Enrique Rodelo barrios
MBMaría Bonilla-Llanos
María Bonilla-Llanos
CRCarlos Rebolledo-Maldonado
Carlos Rebolledo-Maldonado
CDCarmelo Dueñas-Castell
Carmelo Dueñas-Castell
Lung-protective ventilation and other experimental conditions raise arterial carbon dioxide tension (PaCO2) and alter pH. Short-term benefits are reported in non-infectious settings, whereas infection and/or prolonged exposure are typically harmful. This scoping review systematically maps immune-mediated effects of hypercapnia on innate immunity and alveolar epithelial repair. Scoping review per Levac et al. and PRISMA Extension for Scoping Reviews (Open Science Framework protocol: 10.17605/OSF.IO/WV85T; post hoc). We searched original preclinical studies (in vivo/in vitro) in PubMed, Web of Science, ScienceDirect, Cochrane Reviews, and SciELO (2008–2023). PaCO2 (mmHg) was prioritized; %Fraction of inspired Carbon Dioxide (%FiCO2) was recorded when PaCO2 was unavailable; pH was classified as buffered/unbuffered. Data were organized by context, PaCO2, and exposure duration; synthesis used heat maps (0–120 h) and a narrative description for >120 h. Mechanistic axes extracted the following: NF-κB (canonical/non-canonical), Bcl-2/Bcl-xL–Beclin-1/autophagy, AMPK/PKA/CaMKKβ/ERK1/2 and ENaC/Na,K-ATPase trafficking, Wnt/β-catenin in AT2 cells, and miR-183/IDH2/ATP. Thirty-five studies met the inclusion criteria. In non-infectious models, a “protective window” emerged, with moderate PaCO2 and brief exposure (65–95 mmHg; ≤4–6 h), featuring NF-κB attenuation and preserved epithelial ion transport. In infectious models and/or with prolonged exposure or higher PaCO2, harmful signals predominated: reduced phagocytosis/autophagy (Bcl-2/Bcl-xL–Beclin-1 axis), AMPK/PKA/ERK1/2-mediated internalization of ENaC/Na,K-ATPase, depressed β-catenin signaling in AT2 cells, impaired alveolar fluid clearance, and increased bacterial burden. Chronic exposures (>120 h) reinforced injury. Hypercapnia is a context-, dose-, time-, and pH-dependent double-edged modulator. The safe window is narrow; standardized, parallel reporting of PaCO2 and pH—with explicit comparisons of buffered vs. unbuffered hypercapnia—is essential to guide clinical translation.

3 March 2025 in Revista de la Sociedad Ecuatoriana de Nefrología, Diálisis y Trasplante
Verified
Journal Article
Open access
PDF file
TYTomas Rodriguez Yanez
Tomas Rodriguez Yanez
Jorge Rico FontalvoJorge Rico Fontalvo
Jorge Rico Fontalvo
RDRodrigo Daza-Arnedo
Rodrigo Daza-Arnedo
DBDayro Enrique Rodelo barrios
Dayro Enrique Rodelo barrios
CMCarlos Rebolledo M
Carlos Rebolledo M
JEJosser Enrique Jiménez Escobar
Josser Enrique Jiménez Escobar
Introduction: In the ICU, metabolic alkalosis is the most common acid-base disorder. A link has been observed between this disorder and an increased risk of death. However, this increased mortality is likely primarily due to the severity of the underlying disease rather than to metabolic alkalosis itself. Objective of the review: This article is a narrative review aimed at updating the diagnosis, treatment, and prognosis of metabolic alkalosis in the context of intensive care management. Key points of the review: Metabolic alkalosis often develops during a hospital stay and is often a consequence of ICU interventions. Mortality in patients with a pH of 7.55-7.56 is 41%, with a pH of 7.57-7.59 it is 47%, with a pH of 7.60-7.64 it is 65%, and with a pH of 7.65-7.70 it is 80%. Hypokalemia is a significant alteration in metabolic alkalosis, causing muscle weakness and paralysis, areflexia, ileus, ST-segment depression, the presence of a U wave, and QT prolongation. Conclusion: The underlying etiology has a significant influence on mortality associated with metabolic alkalosis. Therapeutic interventions have been limited to guiding adequate fluid management in patients with or without chloride sensitivity; the role of carbonic anhydrase inhibitor-type diuretics has grown, with varying evidence regarding their usefulness.

17 November 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
APAlberto Polo-Barranco
Alberto Polo-Barranco
CRCarlos Rebolledo-Maldonado
Carlos Rebolledo-Maldonado
VEValeria Esquiaqui-Rangel
Valeria Esquiaqui-Rangel
ANAndrea Nuñez-Mejia
Andrea Nuñez-Mejia
JRJeison Rambal-Torres
Jeison Rambal-Torres
EOElber Osorio-Rodríguez
Elber Osorio-Rodríguez
Diabetes mellitus (DM) is associated with a residual cardiovascular risk that persists even when lipid targets are achieved. Within this context, lipoprotein(a) [Lp(a)], an LDL-like particle of genetic origin with pro-atherogenic and antifibrinolytic properties, emerges as a key determinant in the progression of both microvascular and macrovascular complications. Its structural homology with plasminogen promotes thrombosis, while oxidative and glycation modifications amplify endothelial inflammation. Elevated concentrations of Lp(a) (>30 mg/dL; 75 nmol/L), and particularly >50 mg/dL (125 nmol/L), are independently associated with coronary artery disease, ischemic stroke, diabetic nephropathy, retinopathy, and neuropathy. Conventional lipid-lowering therapies exert neutral or modest effects on Lp(a), in contrast with RNA-based targeted agents (antisense oligonucleotides and siRNA[Small Interfering RNA]), which achieve reductions of 70–95% and show consistent results in phase 2 clinical trials. This review integrates molecular mechanisms and clinical evidence, emphasizing the need to incorporate Lp(a) quantification (at least once in a lifetime, and selectively in DM) to refine risk stratification and guide intensive interventions. In diabetic populations, the adaptation of Lp(a)-targeted therapies could redefine the management of residual risk and improve both cardiovascular and microvascular outcomes.